ECSP034568A - Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona - Google Patents

Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona

Info

Publication number
ECSP034568A
ECSP034568A EC2003004568A ECSP034568A ECSP034568A EC SP034568 A ECSP034568 A EC SP034568A EC 2003004568 A EC2003004568 A EC 2003004568A EC SP034568 A ECSP034568 A EC SP034568A EC SP034568 A ECSP034568 A EC SP034568A
Authority
EC
Ecuador
Prior art keywords
triona
pirimidin
type
metaloproteinase inhibitors
inhibitors
Prior art date
Application number
EC2003004568A
Other languages
English (en)
Inventor
Mark Carl Noe
Martin James Wythes
Lawrence Alan Reiter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP034568A publication Critical patent/ECSP034568A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención se refiere a inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona de fórmula En la que X,Y,A,B y,R1 son como se han definido en la memoria descriptiva y a composiciones farmacéuticas y métodos de tratamiento de inflamación cáncer y otros trastornos.
EC2003004568A 2000-10-26 2003-04-25 Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona ECSP034568A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24331400P 2000-10-26 2000-10-26

Publications (1)

Publication Number Publication Date
ECSP034568A true ECSP034568A (es) 2003-06-25

Family

ID=36950891

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004568A ECSP034568A (es) 2000-10-26 2003-04-25 Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona

Country Status (36)

Country Link
US (2) US6706723B2 (es)
EP (1) EP1332136A2 (es)
JP (1) JP2004512327A (es)
KR (1) KR20030061825A (es)
CN (1) CN1714084A (es)
AP (1) AP2001002319A0 (es)
AR (1) AR035362A1 (es)
AU (1) AU2002210800A1 (es)
BG (1) BG107651A (es)
BR (1) BR0114917A (es)
CA (1) CA2425280A1 (es)
CR (1) CR6939A (es)
CZ (1) CZ20031069A3 (es)
EA (1) EA200300409A1 (es)
EC (1) ECSP034568A (es)
EE (1) EE200300195A (es)
GT (1) GT200100214A (es)
HN (1) HN2001000243A (es)
HR (1) HRP20030331A2 (es)
HU (1) HUP0302337A3 (es)
IL (1) IL154946A0 (es)
IS (1) IS6749A (es)
MA (1) MA26956A1 (es)
MX (1) MXPA03003734A (es)
NO (1) NO20031852L (es)
NZ (1) NZ524774A (es)
OA (1) OA12528A (es)
PA (1) PA8531501A1 (es)
PE (1) PE20020585A1 (es)
PL (1) PL362919A1 (es)
SK (1) SK4872003A3 (es)
SV (1) SV2003000704A (es)
TN (1) TNSN01150A1 (es)
UY (1) UY26981A1 (es)
WO (1) WO2002034726A2 (es)
ZA (1) ZA200302192B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287110T3 (es) * 2000-04-11 2007-12-16 Sankyo Company, Limited Composicion farmaceutica estabilizada que contiene un bloqueador de calcio consistente en azelnidipina.
PL362919A1 (en) * 2000-10-26 2004-11-02 Pfizer Products Inc. Pyrimidine-2,4,6-trione metalloproteinase inhibitors
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
EP1368327B1 (en) 2001-02-14 2004-10-20 Warner-Lambert Company LLC Benzo thiadiazine matrix metalloproteinase inhibitors
EP1368323B1 (en) 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US7294624B2 (en) * 2001-12-20 2007-11-13 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US6936620B2 (en) 2001-12-20 2005-08-30 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
ATE304015T1 (de) 2002-04-26 2005-09-15 Pfizer Prod Inc Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
JP2005529895A (ja) * 2002-04-26 2005-10-06 ファイザー・プロダクツ・インク Ｎ置換へテロアリールオキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
MXPA04010550A (es) * 2002-04-26 2005-01-25 Pfizer Prod Inc Inhibidores de metaloproteinasa de pirimidina-2,4,6-triona.
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
CA2497658A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
BR0313459A (pt) 2002-08-13 2005-06-21 Warner Lambert Co Derivados monocìclicos como inibidores de metaloproteinases de matriz
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
JP2006500351A (ja) 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
CN100558362C (zh) * 2004-04-01 2009-11-11 霍夫曼-拉罗奇有限公司 三氧嘧啶治疗和预防支气管炎症疾病的应用
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
EP2427438B1 (en) 2009-05-05 2016-10-12 Cambria Pharmaceuticals, Inc. Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
RU2400233C1 (ru) 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза
KR101301533B1 (ko) * 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
HUE036408T2 (hu) 2011-03-14 2018-07-30 Boehringer Ingelheim Int A leukotrién-termelés benzodioxán inhibitorai
WO2013012844A1 (en) * 2011-07-19 2013-01-24 Boehringer Ingelheim International Gmbh Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase
EP2822942B1 (en) 2012-03-06 2017-05-10 Boehringer Ingelheim International GmbH Benzodioxanes for inhibiting leukotriene production
EA201400976A1 (ru) 2012-03-06 2015-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
US9403830B2 (en) 2012-07-17 2016-08-02 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
WO2014042647A1 (en) * 2012-09-14 2014-03-20 Levina Elizabeth Medicinal drug with activity against gram positive bacteria, mycobacteria and fungi
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2015009611A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
WO2015009609A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2023076679A1 (en) 2021-11-01 2023-05-04 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2002504916A (ja) * 1997-06-21 2002-02-12 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6265578B1 (en) * 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
PA8498701A1 (es) * 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
PL362919A1 (en) * 2000-10-26 2004-11-02 Pfizer Products Inc. Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Also Published As

Publication number Publication date
WO2002034726A9 (en) 2003-03-06
MA26956A1 (fr) 2004-12-20
CZ20031069A3 (cs) 2004-05-12
WO2002034726A3 (en) 2002-10-17
SV2003000704A (es) 2003-01-13
HN2001000243A (es) 2002-11-07
WO2002034726A2 (en) 2002-05-02
NO20031852D0 (no) 2003-04-24
KR20030061825A (ko) 2003-07-22
TNSN01150A1 (fr) 2005-11-10
EE200300195A (et) 2003-10-15
BG107651A (bg) 2003-12-31
MXPA03003734A (es) 2003-07-28
NZ524774A (en) 2004-09-24
EP1332136A2 (en) 2003-08-06
PE20020585A1 (es) 2002-07-06
HRP20030331A2 (en) 2003-06-30
NO20031852L (no) 2003-06-23
OA12528A (en) 2006-06-02
ZA200302192B (en) 2004-05-05
EA200300409A1 (ru) 2003-08-28
US20020132822A1 (en) 2002-09-19
IL154946A0 (en) 2003-10-31
HUP0302337A3 (en) 2004-01-28
SK4872003A3 (en) 2004-08-03
US6706723B2 (en) 2004-03-16
CA2425280A1 (en) 2002-05-02
PL362919A1 (en) 2004-11-02
GT200100214A (es) 2002-07-03
AP2001002319A0 (en) 2001-12-31
IS6749A (is) 2003-03-17
HUP0302337A2 (hu) 2003-10-28
UY26981A1 (es) 2002-06-20
JP2004512327A (ja) 2004-04-22
AR035362A1 (es) 2004-05-12
BR0114917A (pt) 2003-07-01
AU2002210800A1 (en) 2002-05-06
PA8531501A1 (es) 2003-06-30
CN1714084A (zh) 2005-12-28
CR6939A (es) 2003-11-25
US20050107414A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
ECSP034568A (es) Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona
PA8572101A1 (es) Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona
HN2000000137A (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
HN2001000277A (es) PIRROLO [2,1 - a] DIHIDROISOQUINOLINAS
UY27772A1 (es) Inhibidores triariloxiariloxipirimidin-2,4,6- triona de metaloproteinasa.
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
HN1998000091A (es) Inhibidores de la farnesil transferasa tratamiento del cancer.
ATE420636T1 (de) Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
FR2877667B1 (fr) Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
BRPI0407681A (pt) sulfamatos de d-homoestra-1,3,5(10)-trien-3-ila 2-substituìdos ativos antitumorais
SE0001631D0 (sv) New use
PT1358182E (pt) Derivados de diazocinas e sua utilizacao como inibidores de triptase
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
DOP2003000634A (es) Inhibidores de metaloproteinasa de triaril-oxiaril-espiro-pirimidina-2,4,6-triona
DOP2003000633A (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-trionan-sustituida
CR6940A (es) Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasa
ECSP003412A (es) Derivados de 3- amino -3-arilpropan - 1 - ol, su preparacion y su uso
ECSP972332A (es) Derivados de 6-fenilpiridil -2-amina